Want to see AU:AHE full AI Analyst Report?
Top Page
MedAdvisor Limited
(Sydney:AHE)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$0.02
Action:Reiterated
Date:06/23/26
The score is primarily weighed down by poor financial performance, driven by steep revenue contraction, very negative margins, and a highly stressed balance sheet with negative equity. Technicals are also weak with the price below major moving averages, though oversold RSI slightly offsets. Valuation provides limited support due to a negative P/E and no dividend yield data.
Positive Factors
Platform business model
MedAdvisor operates a pharmacy-focused software platform plus a consumer medication app, creating durable product stickiness across pharmacies and patients. This two-sided, workflow-centric model supports recurring engagement (prescription/refill workflows), facilitating long-term customer retention and scalable messaging/telehealth services.
Negative Factors
Steep revenue contraction
A sustained revenue decline of ~39% materially weakens economies of scale, erodes network effects and diminishes recurring revenue predictability. Over several months this reduces pricing power, limits reinvestment in product and sales, and makes restoring growth more challenging without strategic shifts or new partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform business model
MedAdvisor operates a pharmacy-focused software platform plus a consumer medication app, creating durable product stickiness across pharmacies and patients. This two-sided, workflow-centric model supports recurring engagement (prescription/refill workflows), facilitating long-term customer retention and scalable messaging/telehealth services.
Read all positive factors
MedAdvisor Limited (AHE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$10.85M
Dividend YieldN/A
Average Volume (3M)1.73M
Price to Earnings (P/E)―
Beta (1Y)1.82
Revenue Growth-71.80%
EPS Growth-1044.71%
CountryAU
Employees3
SectorHealthcare
Sector Strength45
IndustrySoftware - Application
Share Statistics
EPS (TTM)-0.10
Shares Outstanding637,981,000
10 Day Avg. Volume474,818
30 Day Avg. Volume1,728,714
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)11.59
Price to Sales (P/S)0.19
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$112.30M
MedAdvisor Limited Business Overview & Revenue Model
Company Description
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-drive...
How the Company Makes Money
null...
MedAdvisor Limited Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
30
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.23M | 62.99M | 122.11M | 97.96M | 67.75M | 38.77M |
| Gross Profit | -11.36M | -135.06K | 74.25M | 59.41M | 34.99M | 21.31M |
| EBITDA | -68.81M | -57.25M | 7.05M | -3.03M | -11.29M | -13.59M |
| Net Income | -54.25M | -60.21M | 792.13K | -11.31M | -17.35M | -13.95M |
Balance Sheet | ||||||
| Total Assets | 27.82M | 39.84M | 98.78M | 95.91M | 78.57M | 81.04M |
| Cash, Cash Equivalents and Short-Term Investments | 8.09M | 10.30M | 15.58M | 14.20M | 7.58M | 7.15M |
| Total Debt | 180.92K | 17.40M | 12.61M | 13.09M | 13.41M | 9.16M |
| Total Liabilities | 18.88M | 38.79M | 47.20M | 47.45M | 51.40M | 32.07M |
| Stockholders Equity | 8.94M | 1.05M | 51.58M | 48.46M | 34.55M | 48.45M |
Cash Flow | ||||||
| Free Cash Flow | -14.38M | -14.37M | 5.12M | -1.63M | -548.13K | -12.94M |
| Operating Cash Flow | -14.49M | -14.37M | 5.19M | -1.45M | -236.32K | -12.54M |
| Investing Cash Flow | 2.67M | -2.18M | -2.80M | -3.23M | -290.79K | -43.36M |
| Financing Cash Flow | 7.24M | 11.34M | -831.97K | 12.42M | 1.86M | 50.72M |
MedAdvisor Limited Technical Analysis
―
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AHE, the sentiment is undefined. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for AU:AHE.
MedAdvisor Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$128.98M | 33.45 | 4.37% | ― | 36.43% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$122.76M | -6.22 | -226.75% | ― | 29.37% | -10.38% | |
44 Neutral | AU$21.95M | -3.13 | -1009.84% | ― | 13.69% | 7.57% | |
43 Neutral | AU$15.02M | ― | -578.72% | ― | 43.55% | 26.03% | |
40 Underperform | AU$10.85M | -0.17 | -209.68% | ― | -71.80% | -1044.71% |
* Healthcare Sector Average
AU:AHE
MedAdvisor Limited
0.02
-0.04
-70.69%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.17
-0.08
-34.00%
AU:PHX
PharmX Technologies
0.12
0.02
15.00%
AU:ALC
Alcidion Group Limited
0.10
-0.01
-12.73%
AU:ICR
InteliCare Holdings Limited
0.02
<0.01
46.67%
AU:PCK
PainChek Ltd
0.11
-0.29
-73.08%
MedAdvisor Limited Corporate Events
Adheris Health Cuts Future Dilution as Lapsed Options Reduce Capital Overhang
Jul 10, 2026
Adheris Health Limited, traded on the ASX under the ticker AHE, is a healthcare-focused company that appears to centre its operations on adherence-related health services, utilising option-based incentive schemes within its broader capital managem...
Adheris Health Seeks ASX Quotation for New Share Issue
Jul 8, 2026
Adheris Health Limited has applied to the ASX for quotation of 304,200 new ordinary fully paid shares, issued on June 2, 2026. The application formalizes the listing of these securities following their creation through the exercise or conversion o...
Adheris Health Appoints John Murray to Board with No Initial Securities Interest
Jul 1, 2026
Adheris Health Limited has appointed John Murray as a director effective 1 July 2026, according to an initial director’s interest notice lodged with the ASX. The filing confirms that Murray holds no relevant interests in the company’s ...
Adheris Health Director Sean Slattery Steps Down with No Ongoing Equity Interest
Jul 1, 2026
Adheris Health Limited has announced the departure of director Sean Slattery, who ceased to be a director of the company on 1 July 2026. The company reported that Slattery holds no relevant interests in Adheris Health securities, either directly, ...
Adheris Health Director Increases Equity Stake with On‑Market Share Purchases
May 12, 2026
Adheris Health director John Ciccio has increased his direct holding in the company by acquiring 323,541 fully paid ordinary shares through on‑market trades conducted between 5 and 11 May 2026. The purchases were made at prices of $0.02 and ...
MedAdvisor’s Adheris Health Deepens Pharmacy-Led Patient Engagement Focus
Apr 28, 2026
MedAdvisor’s Adheris Health unit is reinforcing its role as a leader in pharmacy-led patient engagement, working with global pharma and major U.S. pharmacy chains to deliver personalised medication support. The business serves a broad nation...
Adheris Health Revenue Falls but Cost Cuts and Platform Upgrades Aim at Q4 Cash Break-Even
Apr 27, 2026
Adheris Health reported Q3 FY26 operating revenue of $5.4 million, down 23.9% year on year, with gross profit falling to $2.1 million and gross margin slipping to 39.7% amid weaker customer renewals, smaller deal sizes and pharma budget pressures....
Adheris Health Tightens Governance With Updated Securities Trading Policy
Apr 22, 2026
Adheris Health has updated its Securities Trading Policy in line with ASX requirements, releasing a revised framework that governs how its officers and employees can trade in the company’s securities. The board has resolved to replace the pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.